Corcept Therapeutics (CORT) Tax Provisions (2017 - 2026)

Corcept Therapeutics (CORT) has 10 years of Tax Provisions data on file, last reported at -$13.0 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions fell 19.27% year-over-year to -$13.0 million; the trailing twelve-month figure through Mar 2026 stood at -$35.3 million (down 1768.45% YoY), and the FY2025 full-year result was -$33.2 million, down 263.62% from the prior year.
• Tax Provisions advanced to -$13.0 million in Q1 2026, from -$14.4 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $7.7 million in Q4 2022 to a low of -$14.4 million in Q4 2025.
• A 5-year average of $425529.4 and a median of $4.1 million in 2022 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions jumped 411.72% in 2023 and tumbled 1285.26% in 2025, its largest moves.
• Tracing CORT's Tax Provisions over 5 years: stood at $7.7 million in 2022, then fell by 29.4% to $5.4 million in 2023, then sank by 77.59% to $1.2 million in 2024, then plunged by 1285.26% to -$14.4 million in 2025, then advanced by 9.65% to -$13.0 million in 2026.
• Business Quant data shows CORT's Tax Provisions at -$13.0 million in Q1 2026, -$14.4 million in Q4 2025, and -$4.4 million in Q3 2025.